Related Experiment Videos

Danshensu attenuates aldosterone-induced cardiomyocytes injury through interfering p53 pathway

Xiaohong Yang1, Rui Yang1, Xianli Li1

  • 1Department of Cardiovascular, Anyang District Hospital, Anyang, Henan 455000, P.R. China.

Insights

Danshensu (DSS) protects heart cells from aldosterone (ALD)-induced injury by reducing apoptosis. DSS interferes with the p53 signaling pathway, offering potential therapeutic benefits for heart failure patients.

Area of Science:

  • Cardiovascular Disease Research
  • Cellular Biology
  • Pharmacology

Background:

  • Heart failure is a common cardiovascular disease often resulting from cardiomyocyte loss.
  • Excessive aldosterone (ALD) contributes to heart failure by inducing cardiomyocyte hypertrophy and apoptosis.
  • Aldosterone directly targets the heart, exacerbating cardiac dysfunction.

Purpose of the Study:

  • To investigate the protective effects of danshensu (DSS) against aldosterone-induced injury in cardiomyocytes.
  • To elucidate the molecular mechanisms underlying DSS's cardioprotective action.

Main Methods:

  • Primary cardiomyocyte cultures were exposed to aldosterone.
  • Cell viability and lactate dehydrogenase leakage were measured.
  • Apoptosis rates, BAX, Bcl-2, and caspase-3 expression were analyzed.
  • The role of the p53 signaling pathway was investigated.

Main Results:

  • DSS significantly increased cell viability and reduced lactate dehydrogenase leakage in ALD-exposed cardiomyocytes.
  • DSS treatment decreased the apoptotic rate in ALD-stimulated cells.
  • DSS modulated the expression of apoptosis-related proteins (BAX, Bcl-2, caspase-3) via the p53 pathway.

Conclusions:

  • Danshensu (DSS) demonstrates a protective effect against aldosterone-induced cardiomyocyte injury.
  • DSS exerts its beneficial effects by interfering with the p53 signaling pathway.
  • These findings suggest DSS as a potential therapeutic agent for managing aldosterone-related heart conditions.

Related Concept Videos